Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04840394 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Eikon Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04840394 is a Phase 1 study that has completed, run by Eikon Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT04840394, a Phase 1 study, has completed, sponsored by Eikon Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Interventions
- DRUG Pembrolizumab
- DRUG BDB018
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04840394
The ClinicalTrials.gov registry entry for NCT04840394 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04840394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04840394 about?
NCT04840394 is a clinical study titled "Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors". A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
What is the current status of trial NCT04840394?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2021-06-22. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT04840394?
The interventions under investigation include: Pembrolizumab (DRUG), BDB018 (DRUG).
Who is sponsoring clinical trial NCT04840394?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.